Mailing Buprenorphine for Opioid Use Disorder

This trial explores a new method to assist people with opioid use disorder (OUD) by mailing them the medication buprenorphine after hospital discharge. The goal is to simplify treatment adherence by eliminating barriers like pharmacy visits. As a pilot study, it is in the early stages and examines whether this approach is feasible and accepted by patients. Suitable candidates should have OUD, have started buprenorphine in the hospital, and possess a stable mailbox in South Carolina. As an Early Phase 1 trial, this study evaluates the feasibility and acceptance of this innovative treatment approach in real-world settings.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Past studies have shown that buprenorphine is a safe treatment for opioid use disorder (OUD). Research indicates it can lower the risk of overdose and other negative outcomes for patients. For example, some studies found that buprenorphine helps reduce opioid use and increases the likelihood of adherence to treatment plans.

The treatment is well-tolerated, with fewer side effects compared to medications like methadone. Buprenorphine is safe enough to have received approval for treating OUD in various settings, including emergency rooms.

Researchers are excited about mailing buprenorphine for opioid use disorder because it introduces a new method of delivering treatment directly to patients' homes. Unlike traditional methods where patients must visit a clinic or pharmacy to receive their medication, this approach could significantly improve accessibility and convenience, especially for those with mobility issues or living in remote areas. By making it easier for patients to adhere to their medication regimen, this method has the potential to enhance treatment outcomes and reduce the barriers to managing opioid use disorder.

Studies have shown that buprenorphine effectively treats opioid use disorder (OUD). One study revealed that patients taking buprenorphine had a significantly lower risk of death and a higher likelihood of recovery. Another study found that half of the patients who received buprenorphine in an emergency room continued their treatment a month later. Research also indicates that medications like buprenorphine greatly reduce the chances of overdose and death for people with OUD. This trial will assess the feasibility of mailing buprenorphine, potentially making it easier for people to access the medication and remain in treatment.¹⁶⁷⁸⁹